JXL082

JXL082
Clinical data
Other namesJXL-082
Drug classMitochondrial pyruvate carrier (MPC) inhibitor
ATC code
  • None
Identifiers
  • ethyl (E)-3-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]pyrrolo[2,3-b]pyridin-3-yl]-2-cyanoprop-2-enoate
CAS Number
PubChem CID
ChemSpider
ChEMBL
Chemical and physical data
FormulaC22H15F6N3O2
Molar mass467.371 g·mol−1
3D model (JSmol)
  • CCOC(=O)/C(=C/C1=CN(C2=C1C=CC=N2)CC3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)/C#N
  • InChI=1S/C22H15F6N3O2/c1-2-33-20(32)14(10-29)8-15-12-31(19-18(15)4-3-5-30-19)11-13-6-16(21(23,24)25)9-17(7-13)22(26,27)28/h3-9,12H,2,11H2,1H3/b14-8+
  • Key:AIPLDVOUZVHAOG-RIYZIHGNSA-N

JXL082, or JXL-082, is a drug acting as a mitochondrial pyruvate carrier (MPC) inhibitor which was synthesized towards the aim of developing a treatment for hair loss. It is related to other drugs in the same series such as suvomipic (PP405; JXL069) and UK-5099 (JXL001). The drug is known to have been sold online in a grey market fashion for treatment of hair loss. It has been mistakenly believed to be suvomipic in the past. JXL082 was first described in the scientific literature by 2019.

See also